您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > T56-LIMKi(T5601640)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
T56-LIMKi(T5601640)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
T56-LIMKi(T5601640)图片
CAS NO:924473-59-6
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 389.33
Formula C19H14F3N3O3
CAS No. 924473-59-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: ≥ 40 mg/mL
Water:
Ethanol:
Chemical Name 3-Methyl-N-[3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-5-isoxazolecarboxamide
Synonyms T56LIMKi; T56 LIMKi; T56-LIMKi; T-5601640; T 5601640; T5601640
SMILES Code O=C(C1=CC(C)=NO1)NC2=CC=CC(C(NC3=CC=CC(C(F)(F)F)=C3)=O)=C2
实验参考方法
In Vitro

In vitro activity: T56-LIMKi (also known as T5601640) is a potent and selective inhibitor of LIMK2 (LIM kinase 2) with an IC50 of 35.2 μM in a cell (Panc-1 cells) assay. T56-LIMKi inhibits LIMK2 with high specificity, and shows little or no cross-reactivity with LIMK1. T56-LIMKi decreases phosphorylated cofilin (p-cofilin) levels and thus inhibits growth of several cancerous cell lines, including those of pancreatic cancer, glioma and schwannoma. In a nude mouse Panc-1 xenograft model, T56-LIMKi reduced tumor size and p-cofilin levels in the Panc-1 tumors. LIM kinases are important cell cytoskeleton regulators that play a prominent role in cancer manifestation and neuronal diseases. Also LIMKs play a contributory role in several neurodevelopmental disorders and in cancer growth and metastasis. Thus, T56-LIMKi has the potential to be developed as a candidate drug for cancer therapy and neuronal disorders.


Kinase Assay: T56-LIMKi (also known as T5601640) is a potent and selective inhibitor of LIMK2 (LIM kinase 2) with an IC50 of 35.2 μM in a cell (Panc-1 cells) assay.


Cell Assay: NF1 knockout mouse embryonic fibroblasts (MEFs) were prepared from NF1+/- mice, as described previously. MEFs, HeLa, Panc-1, and U-87 cells were grown in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 units/mL penicillin, and 100 μg/ml streptomycin. Cells were incubated at 37°C in a humidified atmosphere of 95% air and 5% CO2. The human NF1 MPNST cell line ST88-14 was obtained from Dr. Nancy Ratner (University of Cincinnati) and maintained in RPMI/15% FCS. A549 cells were maintained in Nutrient Mixture F-12 Ham containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100μg/ml streptomycin. For biochemical and Western blotting assays, cells were plated at 5×105 cells per 10-cm dish or at 15×104 cells per 6-well plate, and for immumofluorescence at 7500 cells per 18-mm glass coverslip. For growth inhibition assays, cells were plated at 5×103 per 24-well plate. All treatments are specified in the text or figure legends.

In Vivo T56-LIMKi causes inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control. Nude CD1-Nu mice (6 weeks old) were housed in barrier facilities on a 12-h light/dark cycle. Food and water were supplied ad libitum. On day zero, 5 × 106 Panc-1 cells in 0.1 ml of PBS were implanted Subcutaneous (s.c.), just above the right femoral joint. S.c. tumors were measured with a caliper, and animal weights were recorded every 4-5 days. Tumor volumes were calculated using the formula: [length × width] × [(length + width)/2]. When tumor volumes reached 0.06–0.07 cm3 (day 0 of treatment), the mice were randomly separated into three groups. Control mice were fed with CMC (vehicle), and T56-LIMKi-treated mice received either 30 or 60 mg/kg of T56-LIMKi daily (by oral administration of 0.1 ml with 0.5% w/v CMC) For imunoblot procedures, tumors were weighed and then homogenized (10% w/v) in lysis buffer as detailed previously. Total amounts of p-cofilin, cofilin and β-tubulin were determined in samples (60 μg protein) of each lysate by SDS-PAGE followed by immunoblotting with the specific antibodies All animal procedures were in accordance with International Laws and Policies.
Animal model Nude CD1-Nu mice (6 weeks old)
Formulation & Dosage Dissolved in 0.5% w/v CMC30 ; 30 or 60 mg/kg; oral administration
References Oncoscience. 2014 Jan 1;1(1):39-48.